TransMedics Group, Inc. - 10-Q Filing
TransMedics Group, Inc. reports Q3 2025 financial results including OCS transplant revenue across lung, liver, and heart product lines.
Tickers: $TMDX
TransMedics Group, Inc. reports Q3 2025 financial results including OCS transplant revenue across lung, liver, and heart product lines.
Tickers: $TMDX